Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

54.27
+3.717.34%
Post-market: 55.421.15+2.12%19:57 EDT
Volume:5.56M
Turnover:305.32M
Market Cap:8.31B
PE:19.60
High:56.87
Open:51.10
Low:49.97
Close:50.56
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:3.94
T/O Rate:3.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.75
PE(LYR):19.59

Loading ...

TG Therapeutics Advances Injectable MS Therapy With New Phase 2 Device Study

TIPRANKS
·
Yesterday

Movement Alert|TG Therapeutics Rises 9.39% in Regular Trading, Trading at $55.29

Market Focus
·
Yesterday

TG Therapeutics rumor highlighted in Betaville blog

TIPRANKS
·
Aug 21

TG Therapeutics jumps 4% to $52.82 after Betaville mention

TIPRANKS
·
Aug 21

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

Simply Wall St.
·
Aug 16

TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?

Simply Wall St.
·
Aug 14

TG Therapeutics price target raised to $21 from $20 at BofA

TIPRANKS
·
Aug 06

TG Therapeutics (TGTX) Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings

Simply Wall St.
·
Aug 06

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)

TIPRANKS
·
Aug 05

TG Therapeutics Earnings Call Signals BRIUMVI Surge

TIPRANKS
·
Aug 05

Movement Alert|TG Therapeutics Rises 5.01% in Regular Trading, Rebounding as Market Re-Prices Q2 Revenue Beat and Raised Full-Year Guidance

Market Focus
·
Aug 05

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Switzerland's Crispr Therapeutics Q2 Casgevy Revenue Jumps 151%, Net Loss Narrows on FDA Approval for Expansion

Reuters
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

TG Therapeutics Down over 11%, on Pace for Largest Percent Decrease Since August 2025

Dow Jones
·
Aug 04

TG Therapeutics falls -10.6%

TIPRANKS
·
Aug 04

Movement Alert|TG Therapeutics Falls 5.35% in Regular Trading, Q2 EPS Misses Estimates by 85%

Market Focus
·
Aug 03

Stock Track | TG Therapeutics Plummets 7% in Intraday Trading After Q2 Earnings Miss Overshadows Strong Revenue and Raised Guidance

Stock Track
·
Aug 03

TG Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03